Marco poletti chiesi

images marco poletti chiesi

He even had an express basis for this in claim 17 as filed and in claim 16 as granted to address this very issue. In clause 4 of this assignment, it was agreed that Vectura would provide a formal assignment of the right to claim priority from D16 for the specific Programme 2 formulations. Patent information events Consult our calendar. From this it is not clear whether only the application or also the priority right had been transferred. The patentee could not file D22 and D23 during the opposition proceedings, in view of a confidentiality agreement with Chiesi. However, pursuant to Article 87 1 EPC, the right of priority may also be invoked by the "successor in title" of the person who has filed the first application.

  • Marco Poletti IP Industry Base
  • EPO T /14 (Pharmaceutical formulations for dry powder inhalers/Vectura Limited) of
  • Chiesi, Gian Marco [WorldCat Identities]
  • Chiesi Farmaceutici S.p.A. IP Industry Base
  • Andrea Chiesi Biography – Andrea Chiesi on artnet

  • Free and open person profile of Marco Poletti, who is Representative before the EPO of Bracco Imaging SpA and is Representative before the EPO of Chiesi. Marco Poletti's email address m******@ | Show email & phone > >> Work, Direttore - Corporate Patent Department @ Chiesi Group.

    Video: Marco poletti chiesi MARCO POLETTI - Interbud Expo - 26-29 Marzo 2013

    Profiles. Marco Poletti (Curriculum Vitae). June Place of birth: Corporate Intellectual Property Patents Director at Chiesi Farmaceutici S.p.A. Direct reporting to.
    The opponent had challenged priority entitlement and had raised lack of novelty over D14 in the statement of opposition.

    Marco Poletti IP Industry Base

    Thus, in the present case, there existed a partial priority for the subject-matter of the Programme 2 formulations, and a separate partial priority for the remaining subject-matter. Consequently, the main request does not meet the requirements of Article 54 3 EPC. The patentee had stated that he did not want to file any further requests. The patentee had argued in reply that he was fully entitled to claim priority from D In point 4 it is specified that Chiesi agrees to file one or more applications taking priority from i.

    Moreover, the confidential status as such of D22 and D23 cannot be seen as a reason to not submit the subject-matter of auxiliary request 4 during the opposition proceedings since the patentee was aware of the partial priority right assigned to Chiesi.

    EPO T /14 (Pharmaceutical formulations for dry powder inhalers/Vectura Limited) of

    images marco poletti chiesi
    Bryan ancheta filipino
    The patentee was therefore adequately warned by the opposition division that D14 was potentially relevant as prior art. Auxiliary requests 1 and 2 did not meet the requirements of Article 2 EPC. Calendar of events Search for events and training by topic, date, location or target audience.

    B is the priority right owned by Chiesi and relates to the specific "Programme 2 formulations" comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone". Oral proceedings took place on 5 May Hence, auxiliary request 2 does not meet the requirements of Article 54 3 EPC.

    SinceI'm R&D Business Controller at the Chiesi Corporate R&D dealing with Performance Management and reporting on actual/planned Marco Poletti.

    metodologici per la valutazione d'azienda e l'analisi degli investimenti reali.

    images marco poletti chiesi

    [ Gian Marco Chiesi; Mario Valletta; Lucia Poletti; Monte Universita Parma Editore.]. Il costo del capitale proprio nella banche: rassegna dei modelli di analisi e verifica empirica per il sistema bancario italiano by GIAN MARCO CHIESI() 1 edition.
    The subject-matter of claim 1 of auxiliary requests 3 and 4 was not novel over D14, for the same reasons as the main request.

    The patentee could not file D22 and D23 during the opposition proceedings, in view of a confidentiality agreement with Chiesi. This restriction has no incidence on the validity of the priority, since the claimed subject-matter still covers embodiments for which the priority is not valid, namely compositions comprising magnesium stearate and active ingredients selected from "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone"; the restriction has also no incidence on the relevance of D14 since this document also discloses magnesium stearate as additive.

    Consequently, the subject-matter of claim 1 as granted encompasses embodiments for which the patent proprietor did not have the priority right and for which therefore the priority is not valid. Reasons for the Decision 1. Thus, in the present case, there existed a partial priority for the subject-matter of the Programme 2 formulations, and a separate partial priority for the remaining subject-matter.

    The amendment brought to claim 1 of this request overcomes all issues as regards the validity of the priority and the relevance of D14 under Article 54 3 EPC.

    images marco poletti chiesi

    images marco poletti chiesi
    Nivea med protection resenha semanal
    Both patent applications were filed on the same date. The opponent had challenged priority entitlement and had raised lack of novelty over D14 in the statement of opposition. Independent claim 1 as granted read as follows: "1.

    B is the priority right owned by Chiesi and relates to the specific "Programme 2 formulations" comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone". Project Page Feedback Known Problems.

    Chiesi, Gian Marco [WorldCat Identities]

    For this purpose, Vectura will provide to Ciesi before 1 February a formal assignment of the right to claim priority for such applications from application 3 D

    Enrica Bucchioni.

    Chiesi Farmaceutici S.p.A. | Chiesi Farmaceutici · clinical development.

    images marco poletti chiesi

    Venerino Poletti. ASL Romagna. Marco Chilosi. University of. Chiesi also claimed priority from D16 for the application D This was an D Declaration from Richard Summersell and Marco.

    Chiesi Farmaceutici S.p.A. IP Industry Base

    Poletti. Matteo Chiesi is on Facebook. Join Facebook to connect with Matteo Chiesi and others you may know. Facebook gives people the power to share and makes.
    Hence, auxiliary request 3 does not meet the requirements of Article 54 3 EPC. Auxiliary request 3 "1. D14 claims a valid priority from application D16which is dated prior to the filing date of the contested patent, whose priority claim is not valid.

    Quality Report Transparency on quality of products and services. Documentation of the appeal procedure can be found in the Register.

    Andrea Chiesi Biography – Andrea Chiesi on artnet

    Online file inspection improvements in the European Patent Register Free webinar on 10 September at Thus, the effect was that Chiesi owned the right to claim priority from D16 for the specific formulations, for which they filed the application D14, whilst maintaining Vectura's right to claim priority from D16 for the opposed patent claiming the general formulations.

    images marco poletti chiesi
    Best mlp funds in last 3 years
    Calendar of events Search for events and training by topic, date, location or target audience. The patentee was therefore adequately warned by the opposition division that D14 was potentially relevant as prior art.

    Video: Marco poletti chiesi Marco Poletti (Personal Branding)

    The arguments of the appellant may be summarised as follows: Validity of the priority Between Vectura and Chiesi existed a joint venture. The patent proprietor hereinafter called appellant filed an appeal against said decision.

    It was correct that Vectura did not have the priority right for invention B, it did however not follow that Vectura's priority claim for invention A was invalid.

    4 Replies to “Marco poletti chiesi”
    1. Auxiliary request 3 - Validity of the priority and novelty over D14 The subject-matter of claim 1 of auxiliary request has been restricted by the size of the carrier particles, which is the same than in D14 see D14, page 12, 3rd par. Most widely held works by Gian Marco Chiesi.

    2. Consequently, the subject-matter of claim 1 as granted encompasses embodiments for which the patent proprietor did not have the priority right and for which therefore the priority is not valid. Documentation of the appeal procedure can be found in the Register.

    3. It follows from that that bringing an entirely fresh case is not in line with the purpose of the appeal proceedings. In Schedule 2 attached to D23, the Programme 2 formulations are identified to be formulations comprising magnesium stearate in combination with specific active agents, namely "formoterol alone, or in combination with beclomethasone or budesonide, and budesonide alone".